Comparative Pharmacology
Head-to-head clinical analysis: FIASP FLEXTOUCH versus FIASP PENFILL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FIASP FLEXTOUCH versus FIASP PENFILL.
FIASP FLEXTOUCH vs FIASP PENFILL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Insulin analog that binds to insulin receptors, lowering blood glucose by facilitating cellular uptake of glucose and inhibiting hepatic glucose production.
Insulin aspart is a rapid-acting insulin analog that lowers blood glucose by stimulating peripheral glucose uptake, especially by skeletal muscle and fat, and by inhibiting hepatic glucose production. It also inhibits lipolysis and proteolysis and enhances protein synthesis.
Subcutaneous injection at mealtime, 0.2-0.4 units/kg per dose, with total daily dose individualized; typically 50-70% of total daily insulin as bolus, remainder as basal.
Subcutaneous injection. Individualized based on blood glucose levels. Typical starting dose for type 1 diabetes: 0.5-1.0 units/kg/day divided into multiple doses, with 50-70% as mealtime insulin and remainder as basal. For type 2 diabetes: 4-6 units with largest meal, titrated up by 2 units every 3-4 days based on glucose monitoring.
None Documented
None Documented
Terminal elimination half-life is approximately 1.3 hours (range 1-1.5 hours) in healthy subjects, corresponding to the rapid clearance of monomeric insulin aspart. This short half-life supports prandial dosing to cover meal-related glucose excursions.
0.5–1.0 hours (subcutaneous); terminal half-life corresponds to absorption rate-limited elimination due to rapid dissociation from insulin receptor.
Renal: approximately 60% of administered insulin is excreted via the kidneys, with the remainder undergoing hepatic metabolism and biliary excretion.
Primarily renal (glomerular filtration and tubular reabsorption); less than 1% excreted unchanged in bile/feces.
Category C
Category C
Insulin Analogue
Insulin Analogue